Temsirolimus
- Generic Name
- Temsirolimus
- Brand Names
- Torisel
- Drug Type
- Small Molecule
- Chemical Formula
- C56H87NO16
- CAS Number
- 162635-04-3
- Unique Ingredient Identifier
- 624KN6GM2T
- Background
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
- Indication
For the treatment of renal cell carcinoma (RCC). Also investigated for use/treatment in breast cancer, lymphoma (unspecified), rheumatoid arthritis, and multiple myeloma.
- Associated Conditions
- Advanced Renal Cell Carcinoma
- Associated Therapies
- -
Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG
- Conditions
- Interventions
- First Posted Date
- 2023-03-17
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Nader Sanai
- Target Recruit Count
- 12
- Registration Number
- NCT05773326
- Locations
- 🇺🇸
St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
Temsirolimus Adventitial Delivery to Improve ANGioplasty And/or Atherectomy Revascularization Outcomes Below the Knee
- Conditions
- Interventions
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Mercator MedSystems, Inc.
- Target Recruit Count
- 250
- Registration Number
- NCT04433572
Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2019-12-13
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT04199026
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Temsirolimus Alone or Paired With Dexamethasone Delivered to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization
- Conditions
- Interventions
- First Posted Date
- 2019-05-08
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Mercator MedSystems, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT03942601
- Locations
- 🇺🇸
Arkansas Heart Hospital, Little Rock, Arkansas, United States
🇺🇸Columbia University Medical Center/NYPH, New York, New York, United States
🇺🇸St. Joseph Hospital of Orange Heart and Vascular Center, Orange, California, United States
Evaluation of a Promising New Combination of Protein Kinase Inhibitors on Organotypic Cultures of Human Renal Tumors
- Conditions
- Interventions
- First Posted Date
- 2018-06-27
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- University Hospital, Grenoble
- Target Recruit Count
- 100
- Registration Number
- NCT03571438
- Locations
- 🇫🇷
Grenoble Alps Hospital, Grenoble, France
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
- Conditions
- Interventions
- First Posted Date
- 2017-09-29
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 720
- Registration Number
- NCT03297606
- Locations
- 🇨🇦
Verspeeten Family Cancer Centre, London, Ontario, Canada
🇨🇦Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦BCCA - Kelowna, Kelowna, British Columbia, Canada
Combination Chemotherapy and Bevacizumab with the NovoTTF-100L(P) System in Treating Participants with Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-06-29
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 52
- Registration Number
- NCT03203525
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
NCT Neuro Master Match - N²M² (NOA-20)
- Conditions
- Interventions
- First Posted Date
- 2017-05-18
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- University Hospital Heidelberg
- Target Recruit Count
- 228
- Registration Number
- NCT03158389
- Locations
- 🇩🇪
University Hospital Mainz, Neurosurgery, Mainz, Germany
🇩🇪University Hospital Heidelberg, Neurology Clinic, Heidelberg, Germany
🇩🇪University Hospital Frankfurt, Neurooncology, Frankfurt am Main, Germany
Temsirolimus Adventitial Delivery to Improve Angiographic Outcomes Below the Knee (TANGO)
- First Posted Date
- 2016-09-20
- Last Posted Date
- 2020-06-11
- Lead Sponsor
- Mercator MedSystems, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT02908035
- Locations
- 🇺🇸
Sanford Research, Sioux Falls, South Dakota, United States
🇺🇸Advocate Christ Medical Center, Oak Lawn, Illinois, United States
🇺🇸St. Joseph Hospital of Orange Heart and Vascular Center, Orange, California, United States
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Conditions
- Interventions
- Drug: SunitinibDrug: Trastuzumab and PertuzumabDrug: Vemurafenib and CobimetinibDrug: PalbociclibDrug: Nivolumab and IpilimumabDrug: AbemaciclibDrug: Atezolizumab and PHESGODrug: Atezolizumab and TalazoparibDrug: Tucatinib plus Trastuzumab Subcutaneous (SC)Drug: FutibatinibDrug: TalazoparibDrug: TemsirolimusDrug: RegorafenibDrug: OlaparibDrug: PembrolizumabDrug: EntrectinibDrug: Larotrectinib
- First Posted Date
- 2016-02-26
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- American Society of Clinical Oncology
- Target Recruit Count
- 3791
- Registration Number
- NCT02693535
- Locations
- 🇺🇸
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸Cancer Treatment Centers of America-Phoenix, Phoenix, Arizona, United States
🇺🇸Sutter Auburn, Auburn, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.